FDA now requires a ll GLP-1 medications to have vision loss warning la

FDA now requires a ll GLP-1 medications to have vision loss warning la

NAION, non-arteritic anterior ischemic optic neuropathy, is a serious eye condition that can cause acute, painless and potentially permanent vision loss.

In light of data that shows that GLP-1 medications are associated with a risk of developing a rare eye condition, NAION, the FDA is now requiring all GLP-1 manufacturers to include a warning label regarding this risk.

NAION, non-arteritic anterior ischemic optic neuropathy, is a serious eye condition that can cause acute, painless and potentially permanent vision loss. The condition occurs when blood flow to the front part of the optic nerve suddenly drops. This sudden drop is much like a stroke in the eye resulting in damage to the optic nerve.

GLP-1 patients who experience sudden, painless loss of vision in one eye or notice blurred vision or hazy central spots should contact their healthcare provider. Other possible symptoms include blind spots, tunnel vision or a distortion of colors. Patients who develop NAION in one eye are at a notably increased risk of developing it in the other eye.